Highly cited articles
Original research
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G Curigliano, H J Burstein, E P Winer, et al.
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
F. Cardoso, A. Costa, E. Senkus, et al.
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A. M. Menzies, D. B. Johnson, S. Ramanujam, et al.
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials
D. Arnold, B. Lueza, J.-Y. Douillard, et al.
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L. Paz-Ares, E.-H. Tan, K. O'Byrne, et al.
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
N. Chaput, P. Lepage, C. Coutzac, et al.
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAFV600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G. V. Long, K. T. Flaherty, D. Stroyakovskiy, et al.
High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients
K. Allenson, J. Castillo, F. A. San Lucas, et al.
European cancer mortality predictions for the year 2017, with focus on lung cancer
M. Malvezzi, G. Carioli, P. Bertuccio, et al.
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
J. C. Osorio, A. Ni, J. E. Chaft, et al.
Guideline papers
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J B A G Haanen, F Carbonnel, C Robert, et al.
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. Moreau, J. San Miguel, P. Sonneveld, et al.
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. E. Postmus, K. M. Kerr, M. Oudkerk, et al.
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
R. Glynne-Jones, L. Wyrwicz, E. Tiret, et al.
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling, E. Campo, O. Hermine, et al.
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
C. Marth, F. Landoni, S. Mahner, et al.
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Hochhaus, S. Saussele, G. Rosti, et al.
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
P G Casali, N Abecassis, S Bauer, et al.
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D Planchard, S Popat, K Kerr, et al.
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A Vogel, A Cervantes, I Chau, et al.
*Data correct as of 17th May 2019
Anapafseos 5 . Agios Nikolaos
Crete.Greece.72100
2841026182
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου